<DOC>
	<DOCNO>NCT00141934</DOCNO>
	<brief_summary>AD 452 new drug develop use adult patient RA . It believe AD 452 may modify underlie disease RA well improve RA symptom , order establish efficacy safety , AD 452 test 3 month study . Patients enrol study already take methotrexate RA remain methotrexate throughout study . An early clinical study 98 subject RA stable background therapy investigate pharmacokinetics , safety tolerability AD 452 take one month . The drug well tolerated significant drug relate adverse event report .</brief_summary>
	<brief_title>A Multicentre Trial Determine Efficacy AD 452 RA Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male/female age 18 75 RA diagnose least 6 month Taking methotrexate least 6 month Must least 4 swollen/tender joint Must pregnant/breastfeeding Must history inflammatory disorder Other condition may lead exclusion trial ( e.g . Diabetes mellitus , malignant melanoma , HIV , active infection , hepatitis B/C , cardiac conduction disorder , hepatic/renal insufficiency , active depression/anxiety/psychosis/schizophrenia convulsion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>ACR20 endpoint</keyword>
	<keyword>Tender/swollen joint</keyword>
	<keyword>Improvement pain</keyword>
	<keyword>Health assessment questionnaire</keyword>
	<keyword>Profile mood state</keyword>
</DOC>